Wird geladen...
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
BACKGROUND: Activated drotrecogin alfa (human activated protein C, rhAPC), is produced by recombinant DNA technology, and purports to improve clinical outcomes by counteracting the inflammatory and thrombotic consequences of severe sepsis. Controversy exists around the clinical benefits of this drug...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2007
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1929064/ https://ncbi.nlm.nih.gov/pubmed/17592639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2253-7-5 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|